Quarterly report pursuant to Section 13 or 15(d)

7. STOCKHOLDERS' EQUITY (Details 2)

v3.19.3
7. STOCKHOLDERS' EQUITY (Details 2) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Total stock-based compensation expense $ 650,670 $ 577,581 $ 2,014,669 $ 1,627,756
Research and development        
Total stock-based compensation expense 95,757 84,588 271,823 246,231
Plasma centers        
Total stock-based compensation expense 13,333 7,836 38,086 22,682
Selling, general and administrative        
Total stock-based compensation expense 491,710 444,651 1,559,530 1,245,702
Cost of product revenue        
Total stock-based compensation expense $ 49,870 $ 40,506 $ 145,230 $ 113,141